Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marker-driven early switch to aflibercept in metastatic colorectal cancer
2012-005657-24Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (CRC), sponsored by University Hospital Ulm. Started Jun 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-005657-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005657-24.